11/18
11:14 am
alxo
ALX Oncology to Present at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
ALX Oncology to Present at Upcoming Investor Conferences [Yahoo! Finance]
11/18
11:00 am
alxo
ALX Oncology to Present at Upcoming Investor Conferences
Medium
Report
ALX Oncology to Present at Upcoming Investor Conferences
11/13
09:53 am
alxo
ALX Oncology (NASDAQ:ALXO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $4.00 price target on the stock.
Low
Report
ALX Oncology (NASDAQ:ALXO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $4.00 price target on the stock.
11/8
07:05 pm
alxo
ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... [Yahoo! Finance]
Low
Report
ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... [Yahoo! Finance]
11/7
08:15 am
alxo
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/30
08:30 am
alxo
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
Medium
Report
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
10/23
12:30 pm
alxo
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Low
Report
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
10/3
09:45 am
alxo
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
Medium
Report
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
10/3
09:05 am
alxo
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
High
Report
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/1
05:53 am
alxo
CD47 Inhibitors Drug Market & Clinical Trials Insight 2026, Featuring Adagene, Akeso, ALX Oncology, EpicentRx, ImmuneOncia, ImmuneOnco Biopharma, Phanes Therapeutics, Virtuoso Therapeutics, and More [Yahoo! Finance]
Low
Report
CD47 Inhibitors Drug Market & Clinical Trials Insight 2026, Featuring Adagene, Akeso, ALX Oncology, EpicentRx, ImmuneOncia, ImmuneOnco Biopharma, Phanes Therapeutics, Virtuoso Therapeutics, and More [Yahoo! Finance]
9/21
09:07 am
alxo
CEO & Director of ALX Oncology Holdings Picks Up 69% More Stock [Yahoo! Finance]
Medium
Report
CEO & Director of ALX Oncology Holdings Picks Up 69% More Stock [Yahoo! Finance]
9/12
08:44 am
alxo
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer [Yahoo! Finance]
High
Report
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer [Yahoo! Finance]
9/12
08:30 am
alxo
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
High
Report
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer